Edwards Lifesciences Corporation (EW)
NYSE: EWHealth CareIndustrial SpecialtiesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
EW stock chart
Technical analysisKey statistics
All statistics- Market cap
- $49.44B
- P/E (TTM)
- 51.06
- Forward P/E
- 25.40
- EPS (TTM)
- $1.68
- Dividend yield
- None
- 52-week range
- 72.30 – 96.29
- Day range
- 85.49 – 87.30
- Volume / Avg
- 3.51M / 3.82M
- Beta
- —
- Shares outstanding
- 576.40M
- Next earnings
- Oct 29, 2026
52-week range
EW stock today
Shares of Edwards Lifesciences (EW) finished lower on Oct 7 at $85.78, a drop of 0.81% or $0.70 per share, versus the S&P 500's 0.22% decline. At this level, EW sits in the middle of its 52-week range of $72.30 to $96.29: 10.9% below the high, set on Jul 7, 2026 and 18.6% above the low. EW is up 0.6% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 11.8%.
At 51.1x trailing earnings, Edwards Lifesciences trades above the peer-group median of 23.3x. Its forward P/E of 25.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Edwards Lifesciences's next earnings report is expected on Oct 29, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Edwards Lifesciences
Company profileEdwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.
- Sector
- Health Care
- Industry
- Industrial Specialties
- CEO
- Mr. Bernard J. Zovighian
- Headquarters
- Irvine, CA
- Employees
- 16,000
- Website
- edwards.com
Financial highlights
Full financialsIn fiscal 2025, Edwards Lifesciences generated $6.07 billion in revenue, up 11.5% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $1.07 billion (-74.3% year over year), for a net margin of 17.7% versus a median of 28.7% in the prior 5 years. Gross margin was 78.0% (down from 79.5%) and operating margin 20.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B |
| Growth | +11.55% | +8.57% | +12.23% | -14.69% | +19.29% |
| Net income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B |
| EPS (diluted) | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 |
Analyst forecast
ForecastConsensus (29 analysts)
buy
Avg. price target
$101.96+18.86%
- Strong buy 5
- Buy 18
- Hold 6
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 29, 2026
- EPS estimate
- $0.73
- Last reported (Q2 2026)
- Aug 4, 2026
- EPS actual vs est.
- $0.42 vs —
EW news
All EW news- Barclays Initiates Coverage of Edwards Lifesciences at OverweightNasdaqEW, BCS
- Stryker, Abbott among Overweight ideas as Barclays turns bullish on MedTechSeeking AlphaEW, BCS, SYK
- Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?NasdaqISRG, EW, GKOS
- Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report DataNasdaqABBV, AZN, CBLL, CDXS
- Edwards Secures FDA Approval For First Adjustable Pulmonary Valve For ChildrenNasdaq
- Edwards Wins FDA Approval For First Pediatric Surgical Pulmonary ValveNasdaq
- Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity AheadNasdaq
- Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit TranscriptSeeking AlphaEW, DB
Edwards Lifesciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| STESTERIS plc (Ireland) | 209.68 | +0.49% | $20.44B | vs EW |
| ZBHZimmer Biomet Holdings Inc. | 88.49 | -1.33% | $16.88B | vs EW |
| MASMasco Corporation | 68.87 | -1.52% | $13.58B | vs EW |
| AITApplied Industrial Technologies Inc. | 334.58 | -3.02% | $12.29B | vs EW |
| SNNSmith & Nephew SNATS Inc. | 26.89 | +0.07% | $11.25B | vs EW |
| ALGNAlign Technology Inc. | 139.87 | -1.12% | $9.94B | vs EW |
| MSAMSA Safety Incorporated | 179.28 | -1.74% | $6.92B | vs EW |
| MTRNMaterion Corporation | 290.72 | -6.87% | $6.06B | vs EW |
Indexes, lists and sector
Index membership
Edwards Lifesciences stock FAQ
What is Edwards Lifesciences's stock price today?
EW last traded at $85.78 as of Oct 7, 4:00 PM EDT, down 0.81% on the day. Prices are delayed at least 15 minutes.
Does Edwards Lifesciences pay a dividend?
No. Edwards Lifesciences does not currently pay a regular cash dividend.
When is Edwards Lifesciences's next earnings date?
Edwards Lifesciences is expected to report earnings on Thursday, October 29, 2026. Analysts expect EPS of $0.73.
What is EW's P/E ratio?
EW trades at a trailing P/E ratio of 51.06 and a forward P/E of 25.40, compared with a median of 23.3 for its closest peers.
Is Edwards Lifesciences in the S&P 500?
Yes. Edwards Lifesciences (EW) is a constituent of the S&P 500 index.
Who is Edwards Lifesciences's CEO?
Mr. Bernard J. Zovighian is the chief executive officer of Edwards Lifesciences Corporation, which has about 16,000 employees.
Has EW ever split its stock?
Yes. The most recent EW stock split was a 3-for-1 split on Jun 1, 2020, one of 3 splits on record.